Hydrazine-Containing Heterocycle Cytochalasan Derivatives From Hydrazinolysis of Extracts of a Desert Soil-Derived Fungus Chaetomium madrasense 375

Qingfeng Guo, Jinhua Chen, Yuwei Ren, Zhenhua Yin, Juanjuan Zhang, Baocheng Yang, Xuewei Wang, Wenbing Yin, Wancun Zhang, Gang Ding and Lin Chen

Chengzhou Key Laboratory of Synthetic Biology of Natural Products, Chengzhou Key Laboratory of Medicinal Resources Research, Comprehensive Utilization of Edible and Medicinal Plant Resources Engineering Technology Research Center, Huanghe Science and Technology College, Chengzhou, China, 2 Department of Pharmacy, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Chengzhou, China, 3 State Key Laboratory of Mycology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China, 4 Henan Key Laboratory of Children’s Genetics and Metabolic Diseases, Children’s Hospital Affiliated to Zhengzhou University, Chengzhou, China, 5 Institute of Medicinal Plant Development, Chinese Academy of Medical Science and Union Medical College, Beijing, China

“Diversity-enhanced extracts” is an effective method of producing chemical libraries for the purpose of drug discovery. Three rare new cytochalasan derivative chaetoglobosins B1–B3 (1–3) were obtained from chemically engineered crude broth extracts of Chaetomium madrasense 375 prepared by reacting with hydrazine monohydrate and four known metabolite chaetoglobosins (4–7) were also identified from the fungus. The structures were identified by NMR and MS analysis and electronic circular dichroism simulation. In addition, the antiproliferative activities of these compounds were also evaluated, and the drug-resistant activities of cytochalasans were evaluated for the first time. Compound 6 possessed potent activity against four human cancer cells (A549, HCC827, SW620, and MDA-MB-231), and two drug-resistant HCC827 cells (Geftinib-resistant, Osimertinib-resistant) compared with the positive controls.

Keywords: diversity-enhanced, cytochalasans, antiproliferative activity, chaetomium madrasense, hydrazinolysis

INTRODUCTION

Natural products have played an important role in the development of novel drugs because of their established structural diversity (Newman and Cragg, 2016). However, research on natural products within the pharmaceutical industry has recently declined, and it has become more and more difficult to obtain compounds bearing skeletal novel structures from natural sources (Bradshaw et al., 2001; Wolfender and Queiroz, 2012). Chemical modification of natural product extracts provides a new strategy for discovering of diverse structurally active molecules. Recently, there have been several reports (Lopez et al., 2007; Mendez et al., 2011; Salazar et al., 2011; Ramallo et al., 2012; Kikuchi et al., 2014; Wu et al., 2015; Garcia et al., 2016) on the application of chemical alteration of natural product extracts to obtain new or bioactive compounds.
Cytochalasans comprise a large group of polyketide synthase and non-ribosomal peptide synthetase-derived fungal metabolites with a wide range of biological activities (Scherlach et al., 2010). The macrocyclic structure of most cytochalasans contains carbonyl functional groups, which could react with hydrazine to form either hydrazones or acyl hydrazides that rarely emerge in nature. This transformation could increase the nitrogen content and nucleophilic character of further reactions (Feher and Schmidt, 2003). In previous studies, we reported several bioactive cytochalasans that were isolated from C. madrasense 375 derived from desert soil (Guo et al., 2019). To gain more novel cytochalasan-like bioactive compounds, a chemical transformation of crude broth extracts of C. madrasense 375 with hydrazine monohydrate was performed, followed by purification of reaction products, which offered three new cytochalasans derivatives chaetoglobosins B1–B3 (1–3), and known chaetoglobosin B (4) (Sekita et al., 1982, 1983) chaetoglobosin D (5) (Sekita et al., 1982, 1983), chaetoglobosin E (6) (Sekita et al., 1976), and cytoglobin A (7) (Cui et al., 2010) were also isolated from the unreactive raw extract of this fungus. In this paper, we present the isolation, structure elucidation, bioactivities, and plausible synthesis pathways of these compounds.

MATERIALS AND METHODS

General Experimental Procedures

CD spectra were determined on a JASCO J-810 spectropolarimeter (JASCO Corporation), and UV data were recorded using a PERSEE UV-VIS spectrophotometer T9 (Beijing, China). NMR experiments were carried out on a Bruker AVANCE III 400 NMR spectrometer (Bruker, Germany), using tetramethylsilane (TMS) or solvent signals as an internal reference. HRESIMS data were collected on an Agilent 6250 TOF LC/MS, and ESIMS data were acquired on an Agilent 6120QTOF LC/MS, and ESIMS data were acquired on an Agilent 6250 TOF LC/MS system. Semipreparative HPLC was run on a Calmflowplus system that was equipped with a YMC Pack ODS-A column (10 mm × 250 mm 5 μm, Japan) and a 50D UV-vis Detector (Lumiere Tech Ltd) and with a flow rate of 2.0 ml/min. Packing materials for column chromatography were silica gel (200–300 mesh; Qingdao Marine Chemical Factory, Qingdao, China), ODS (YMC, Japan), and Sephadex LH-20 (GE Healthcare BioSciences AB, Sweden). All chemicals used in the study were of analytical grade.

Fungal Material and Fermentation

The samples of the fungus C. madrasense375 (CCTCC M 2019517 CLC375) were collected from a soil sample obtain at Hotan city, Xinjiang province, People’s Republic of China, and identified by one of the authors (XueWei Wang). The fungus was identified as C. madrasense according to its internal transcribed spacer (ITS) sequence of ITS rDNA (Supplementary Figure 34) and beta-tubulin encoding gene (Supplementary Figure 33) from genomic DNA, as well as its morphological features. A phylogenetic tree was constructed based on the sequence of the partial beta-tubulin gene from C. madrasense and other species in the genus Chaetomium, with Aspergillus nidulans as the outgroup (Supplementary Figure 32). The sequence of the strain was deposited in GenBank with accession number KP269060.1. The fungal strain was maintained on potato dextrose agar (PDA) at 25°C for 7 days to prepare the seed culture. Agar plugs were cut into small pieces (approximately 1 cm × 1 cm) and inoculated into four 500 ml Erlenmeyer flasks containing 200 ml of synthetic dropout Medium (SD, peptone 10.0 g/L, dextrose 40.0 g/L) and incubated at 26°C for 10 days on a rotary shaker (120 rpm). The obtained liquid seeds were transferred into fifty 500 ml Erlenmeyer flasks, each containing 200 ml of the sterilized synthetic dropout medium and incubated at 26°C for 35 days on a rotary shaker (120 rpm) before harvest. The culture was filtered to separate broth and mycelia, and then extracted by ethyl acetate (three times) at room temperature. The combined extracts of broth and mycelia were dried under reduced pressure to give a dark brown gum (8.3 g). The crude extract was then suspended in H2O and extracted with petroleum ether, EtoAc, and n-BuOH, respectively. The EtoAc extract (5.6 g) was packed with cytochalasans based on the analysis of TLC and LC-MS experiments and divided into two parts, one (4 g) prepared for chemical modification, another (1.6 g) for metabolite research directly.

Chemical Modification of Extraction and Isolation

An EtoH solution of the dry extract (3% wt/vol) containing hydrazine monohydrate (6 % vol/vol) and three drops of hexahydropyridine was stirred under reflux at 75°C for 8 h, and the solvent was removed under reduced pressure. The preliminary experiment was carried out on a 100 mg scale to obtain modified production successfully and prove feasibility. The obtained residue was subjected to an ODS column eluted with CH3OH/H2O (30, 50, 70, and 100%, v/v) to afford four main fractions (A-D). Fraction C was chromatographed by Sephadex LH-20 (100% MeOH) to give 10 subfractions (C-1–C-10), Fraction C-1 was further purified via semipreparative HPLC (37% MeCN in H2O) to yield chaetoglobosin B1 (1; 2.5 mg, tR 16.1 min). Fraction C-3 was further purified by semipreparative HPLC using 32% acetonitrile in water to afford chaetoglobosin B3 (3; 5.8 mg, tR 32.3 min). Chaetoglobosin B2 (2; 4.3 mg, tR 24.6 min) was purified from subfraction C-5 by RP-HPLC using 35% acetonitrile in water. The unreactive raw extract (1.6 g) was subjected to Sephadex LH-20 (CH2Cl2/MeOH, v/v, 1:1) to yield five fractions (Fr1–Fr5). Fraction 3 was separated using semipreparative HPLC (45% MeCN in H2O with 0.1% HCOOH) to give chaetoglobosin B (4; 8.7 mg, tR 31.5 min), chaetoglobosin D (5; 6.3 mg, tR 24.9 min), and chaetoglobosin E (6; 4.6 mg, tR 21.7 min). Cytoglobin A (7; 1.3 mg, tR 19.4 min) was obtained from fraction 4 using semipreparative HPLC (50% MeCN in H2O with 0.1% HCOOH).

Chaetoglobosin B1 (1): white amorphous powder; UV (MeOH) λmax (log ε) 281 nm (2.00), 225 nm (3.02), and 221 nm (3.01); for 1H NMR (400 MHz) and 13C NMR (100 MHz) data, see Tables 1, 2; HR-ESI-MS m/z 543.2950 [M+H]+ (calcd for C32H30N4O4, 543.2966).
TABLE 1 | $^1$H NMR spectroscopic data (δ in ppm, J in Hz) for compounds 1–3.

| No. | 1$^a$ | 2$^b$ | 3$^c$ |
|-----|-------|-------|-------|
| 1   | 10.89 (1H, br s) | 8.42 (1H, s) |
| 2   | 6.89 (1H, br s) | 6.98 (1H, br s) | 7.27 (1H, br s) |
| 4   | 7.38 (1H, d, 7.7) | 7.28 (1H, d, 7.9) | 7.46 (1H, d, 7.6) |
| 5   | 6.99 (1H, t, 7.2) | 6.95 (1H, t, 7.5) | 6.97 (1H, t, 7.2) |
| 6   | 7.06 (1H, t, 6.9) | 7.05 (1H, t, 7.5) | 7.06 (1H, t, 6.9) |
| 7   | 7.31(1H, d, 8.1) | 7.33 (1H, d, 8.0) | 7.35 (1H, d, 8.1) |
| 2   | 7.82 (1H, br s) |
| 3   | 3.58 (1H, dd, 9.8, 5.2) | 3.55 (1H, t, 6.0) | 3.38 (1H, m) |
| 4   | 3.33 (1H, s) | 3.28 (1H, br s) | 3.82 (1H, s) |
| 5   | 7.31 (1H, d, 8.1) | 7.33 (1H, d, 8.0) | 7.35 (1H, d, 8.1) |
| 6   | 2.78 (1H, d, 13.9, 5.2) | 2.76 (1H, d, 14.2, 5.5) | 2.78 (1H, d, 14.5, 5.7) |
| 7   | 1.16 (3H, s) | 1.27 (3H, s) | 1.00 (3H, s) |
| 8   | 1.64 (3H, s) | 1.56 (3H, s) | 1.52 (3H, s) |
| 9   | 5.91 (1H, dd, 14.2, 10.3) | 1.80 (1H, m) | 6.25 (1H, dd, 14.6, 10.6) |
| 10  | 4.79 (1H, m) | 0.30 (1H, m) | 4.56 (1H, m) |
| 11  | 2.11 (1H, d, 11.0) | 0.64 (1H, m) | 2.20 (1H, m) |
| 12  | 1.73 (1H, d, 13.7) | 0.22 (1H, m) | 1.99 (1H, m) |
| 13  | 2.23 (1H, m) | 1.15 (1H, m) | 2.36 (1H, m) |
| 14  | 4.75 (1H, m) | 1.05 (1H, m) | 5.40 (1H, d, 9.4) |
| 15  | 1.80 (1H, m) | 2.36 (1H, m) | 1.05 (1H, m) |
| 16  | 1.78 (1H, m) | 1.56 (1H, m) | 1.52 (1H, m) |
| 17  | 4.11 (1H, d, 3.9) | 5.05 (1H, s) | 5.10 (1H, s) |
| 18  | 5.17 (1H, d, 4.0) | 7.76 (1H, d, 8.7) |
| 19  | 5.98 (1H, s) | 8.00 (1H, d, 8.9) | 6.39 (1H, s) |
| 20  | 5.87 (3H, d, 6.8) | 0.72 (3H, d, 6.8) | 0.94 (3H, d, 6.8) |
| 21  | 1.69 (3H, s) | 1.21 (3H, d, 6.8) | 1.35 (3H, s) |

$^a$Measured in CD$_3$OD. $^b$Measured in DMSO-d$_6$. $^c$Measured in DMSO-d$_6$ with one drop CD$_3$OD.

Chaetoglobosin B$_2$ (2): white amorphous powder; UV (MeOH) $\lambda_{\text{max}}$ (log $\varepsilon$) 279 nm (1.21) and 211 nm (3.23); for $^1$H NMR (400 MHz), and $^{13}$C NMR (100 MHz) data, see Tables 1, 2; HR-ESI-MS m/z 529.3184 [M+H]$^+$ (calcd for C$_{32}$H$_{41}$N$_4$O$_3$, 529.3173).

Chaetoglobosin B$_3$ (3): white amorphous powder; UV (MeOH) $\lambda_{\text{max}}$ (log $\varepsilon$) 282 nm (0.31), and 211 nm (3.23); ECD (MeOH) $\lambda_{\text{max}}$ ($\Delta\varepsilon$) = 286 nm (+14.5), 224 (--27.2); for $^1$H NMR (400 MHz) and $^{13}$C NMR (100 MHz) data, see Tables 1, 2; HR-ESI-MS m/z 567.2738 [M+H]$^+$ (calcd for C$_{32}$H$_{35}$N$_6$O$_4$, 567.2714).

Quantum-Chemical Calculation

Monte Carlo conformational searches were run with the Spartan 14 software using the Merck Molecular Force Field (MMFF). The Selected conformers, which account for more than 1% of the Boltzmann distribution, were initially optimized at the B3LYP/6-31+G (d, p) level with the conductor-like polarizable continuum (CPCM) conductor calculation in methanol solvent. The conformers of 3 were identified via ECD simulation using the time-dependent density functional theory (TD-DFT) method at the B3LYP/6-31+G (d, p) level with methanol as solvent, and the rotational strengths of 30 excited states were calculated. ECD spectra of compound 3 were obtained using the SpecDis 1.6 (University of Würzburg, Würzburg, Germany) and GraphPad Prism 5 (University of California San Diego, USA) software by applying Gaussian band shapes with sigma = 0.3 eV from dipole-length rotational strengths (Guo et al., 2019).

Antiproliferative Assay

Antiproliferative activity was performed against four human cancer cell lines (A549, SW620, MDA-MB-231, and HCC827), together with two drug-resistant (gefitinib, osimertinib) HCC827 cell lines, applying the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) method (Chen et al., 2014) with the DDP (cisplatin, Sigma), gefitinib, and...
RESULTS AND DISCUSSION

The ethyl acetate extract of C. madrasense 375 was obtained from the submerged fermentation liquid and divided into two parts; part 1 was treated with hydrazine monohydrazine and hexahydropyridine (catalyst) to give a chemically modified production. HPLC (Supplementary Figure 35) and $^{13}$C NMR (Supplementary Figure 36) were performed to analyze changes in the extract. Modified production and raw extract were further separated and purified through reversed-phase C18 (ODS) column chromatography, Sephadex LH-20, as well as semipreparative HPLC to afford compounds 1–7 (Figure 1).

Identification of Compounds

Chaetoglobosin B$_1$ (1) was obtained as a white amorphous powder. The molecular ion peak in the HR-ESI-MS ($m/z$ 543.2950 [M+H]$^+$) (Supplementary Figure 7), calcld for 543.2966, C$_{32}$H$_{30}$N$_4$O$_4$ and NMR data indicated that the molecular formula of 1 is C$_{32}$H$_{38}$N$_4$O$_4$ (16 unsaturations). Combined $^1$H and $^{13}$C NMR spectra (Tables 1, 2; Supplementary Figures 1, 2) and HSQC (Figure 2; Supplementary Figure 4), HMBC (Figure 2; Supplementary Figure 5) experiments indicated the presence of four methyl groups, two methylene units, seven methine units, one quaternary carbon, 16 olefinic or aromatic carbons, as well as one amide carbonyl carbon. The characteristic signals of $^1$H and $^{13}$C NMR spectra (Tables 1, 2; Supplementary Figures 1, 2) suggested that compound 1 was most likely a chaetoglobosin derivative (Gao et al., 2019; Chen et al., 2020). Detailed analysis of the $^1$D (Supplementary Figures 1, 2) spectra of 1 revealed a close similarity with those reported chaetoglobosin B (4) (Sekita et al., 1982, 1983), except that the C-20, C-21, C-22, and C-23 signals at $\delta$C 197.3, 136.0, 136.4, and 201.3 in chaetoglobosin B (4) were replaced by $\delta$C 73.0, 147.0, 102.6, and 155.0 in 1, respectively. The chemical shift values of C-20 ($\delta$C = 73.0) and C-23 ($\delta$C = 155.0) revealed the connection with the additional nitrogen or oxygen atom. Comparison of the molecular formula for chaetoglobosin B (4) and 1 also was found to contain two additional nitrogen atoms, with the C-20, C-21, C-22, and C-23 carbons to constitute a pyridazin ring. Furthermore, the HMBC correlations (Figure 2; Supplementary Figure 5) from H-20 to C-18, C-19 and C-21, H-22 to C-21 and C-23, as well as $^1$H–$^1$H COZY correlations (Figure 2; Supplementary Figure 3) of H-20/H-19 supported this deduction. In the NOESY spectrum (Supplementary Figure 3), the relative configurations of H-4 supported this deduction. In the NOESY spectrum (Supplementary Figure 3), the relative configurations of H-4, H-8 were assigned as $\beta$-orientations based on cross-peaks of H-4/H-8/H-14, and H-7/H-13 implied that H-7 was $\alpha$-orientation. Furthermore, correlations from H-13 and H-17 to 15a ($\delta$H 1.73) and from H-17 to H-19 and H-16-Me suggested that 16-Me and H-19 were cofacial and $\alpha$-oriented. Correlations between H-16 and H-18-Me and large coupling constants ($J = 14.2$ Hz) confirmed the double bonds (13α and 17α) to be E-geometry, and the relative configuration of 1 was identical to that of reported chaetoglobosin B. Therefore, the structure of compound 1 was unambiguously assigned by a detailed analysis of the 1D and 2D NMR spectra (Figure 2; Supplementary Figures 1–6).

TABLE 2 $^{13}$C NMR spectroscopic data (δ in ppm) for compounds 1–3.

| NO | $^1$α | $^2$β | $^3$γ |
|----|-------|-------|-------|
| 1a | 138.1 C | 136.2 C | 136.2 C |
| 2 | 124.6 C | 123.1 C | 123.8 CH |
| 3 | 112.1 C | 110.5 C | 110.7 C |
| 3a | 128.6 C | 127.0 C | 127.5 C |
| 4 | 119.3 CH | 118.0 CH | 118.2 CH |
| 5 | 119.8 CH | 118.3 CH | 118.3 CH |
| 6 | 119.8 CH | 118.3 CH | 118.3 CH |
| 7 | 112.3 CH | 111.4 CH | 111.5 CH |
| 1 | 179.2 C | 173.8 C | 175.8 C |
| 3 | 60.1 CH | 56.4 CH | 58.3 CH |
| 5 | 53.6 CH | 50.9 CH | 47.1 CH |
| 7 | 128.4 C | 125.3 C | 126.1 C |
| 8 | 56.4 CH | 50.3 CH | 55.8 CH |
| 9 | 51.5 C | 50.0 C | 49.1 C |
| 10 | 32.5 CH$_2$ | 31.9 CH$_2$ | 31.9 CH$_2$ |
| 11 | 17.4 CH$_3$ | 17.1 CH$_3$ | 16.9 CH$_3$ |
| 12 | 14.7 CH$_3$ | 15.2 CH$_3$ | 14.4 CH$_3$ |
| 13 | 129.9 CH | 25.2 CH$_2$ | 130.7 CH |
| 14 | 135.1 CH | 27.7 CH$_2$ | 133.1 CH |
| 15 | 43.0 CH | 34.6 CH$_2$ | 42.3 CH$_2$ |
| 16 | 33.1 CH | 31.5 CH | 32.4 CH |
| 17 | 137.8 CH | 30.2 CH$_2$ | 136.5 CH |
| 18 | 135.3 CH | 34.4 CH | 133.4 CH |
| 19 | 82.4 CH | 75.8 CH | 75.6 CH |
| 20 | 73.0 CH | 165.5 C | 143.4 C |
| 21 | 147 C | 123.5 CH | 128.9 C |
| 22 | 102.6 CH | 125.1 CH | 105.2 C |
| 23 | 155 C | 163.0 C | 152.0 C |
| 16-Me | 21.8 CH$_3$ | 21.0 CH$_3$ | 21.6 CH$_3$ |
| 18-Me | 12.7 CH$_3$ | 21.9 CH$_3$ | 9.6 CH$_3$ |

*a Measured in CD$_3$OD. b Measured in DMSO-d$_6$. * Measured in DMSO-d$_6$ with one drop CD$_3$OD.
osimertinin as positive controls, respectively. The cell lines were cultured in RPMI-1640 medium supplemented with 10% FBS at 37°C under a humidified atmosphere of 5% CO$_2$. Cells (3 × 10$^4$/well) were seeded in a 96-well plate and incubated for 24 h. The test compounds at different concentrations were added to each well and further incubated for 24 or 48 h under the same conditions. Then, 10 μl of the MTT was added to each well at a concentration of 5 mg/ml and incubated for 4 h. The medium containing MTT was then gently replaced by DMSO and pipetted to dissolve any formazan crystals formed. Absorbance was then determined on a Tecan Sunrise microplate reader at 490 nm. The concentration required to inhibit cell growth by 50% (IC$_{50}$) was calculated from inhibition curves.
Chaetoglobosin B2 (2) is a white amorphous powder with the molecular formula C_{32}H_{40}N_{4}O_{3} (15 unsaturations) as deduced from an ion at m/z 529.3184 [M+H]^+ in the HR-ESI-MS (Supplementary Figure 17). The comparison of the ¹H and ¹³C NMR data (Tables 1, 2) between 1 and 2 showed that both possess a similar chaetoglobosin skeleton, with the difference as follows: the four olefinic carbons at C-13 (129.9), C-14 (135.1), C-17 (137.8), and C-18 (133.5) in 1 were replaced by alkyl carbons (C-13, 25.2; C-14, 27.7; C-17, 30.2; C-18, 34.4) and one amino carbon (73.0, C-20) instead of by an imine carbon (165.5, C-20); the hydroxy group at C-21 disappeared, supported by the proton and carbon resonances at δH 7.76 (br d, 8.7, H-22) and C-21 (125.1) in 2. Furthermore, the observed ¹H-¹H COSY correlation (Figure 2; Supplementary Figure 13) of H-8/H-13/H-14/H-15/H-16/H-17/H-18/H-19 as well as HMBC correlations (Figure 2; Supplementary Figure 15) from H-19 to C-17, C-18-Me, and C-20, from H-21 to C-22 and C-23, from H-22 to C-20 and C-21, and from H-4 to C-23 confirmed the above deduction. The configuration of 2 at H-3, H-4, H-7, H-8, and H-16 was defined to be identical to 1 and known chaetoglobosin B based on the comparison of the NMR data. The Z-geometry of the Δ_{2,11}-double bond was deduced by the
The Plausible Synthesis Pathway

The putative synthesis pathway for compounds 1–3 was proposed starting from chaetoglobosin B through hydrazinolysis reaction. The precursor chaetoglobosin B underwent an intermolecular nucleophilic addition-elimination reaction with hydrazine, catalyzed by hexahydropyridine to give the intermediates i, followed by [1, 4] addition, ring opening, isomerization, and [1, 5] proton transfer reactions to lead to the formation of 1 (Scheme 1A). 2 was formed by an elimination and hydrogenation reduction of intermediates i (Scheme 1A). 3 was an unexpected production of cytochalasin and hydrazine monohydrate. There was little literature on the formation of 3 and its analogs. Herein, we surmised that 3 may be not directly produced by cytochalasin and hydrazine monohydrate. Therefore, we propound that 3 may be formed by cycloaddition of cytochalasans and the oxidation of hydrazine monohydrate. The plausible pathway of 3 is proposed as shown in Scheme 1B.

Biological Activity

Compounds 1–7 were evaluated for their inhibitory effects toward human non-small-cell lung carcinoma (A549, HCC827), human colon cancer (SW620), and human breast cancer (MDA-MB-231) cell lines. As shown in Table 3, compounds 1 and 7 exhibited selected antiproliferative activity on non-small-cell lung carcinoma A549 and human colon cancer SW620 cells, respectively. Compound 4 showed selected antiproliferative activity on three cancer cell lines, HCC827, SW620, and MDA-MB-231 with IC\textsubscript{50} values of 11.6, 8.8, and 11.4 μM, respectively. Compound 5 displayed moderate antiproliferative activity on four cancer cell lines with the IC\textsubscript{50} values ranging from 6.9 to 10.6 μM. It is noteworthy that compound 6 possessed potent activity (IC\textsubscript{50} values ranging from 1.7 to 9.9 μM), which were all stronger than the positive control cisplatin. In addition, compound 6 showed a more significant inhibitory effect on two drug-resistant HCC827 cells (Gefitinib-resistant, Osimertinib-resistant) with IC\textsubscript{50} values of 5.1 and 2.8 μM, respectively. However, compounds 2–3 showed no obvious inhibitory effect (IC\textsubscript{50} > 20 μM). According to the result of the cytotoxicity assay (Tables 3, 4), it is worth noting that the heterocyclic ring fused into the macrocyclic of compounds 1–3 may be reduced the activity by blocking the interaction with its site of action.

CONCLUSION

As a fungus, the Chaetomium genus contains more than 100 species and plenty of structural novel metabolites (including cytochalasans) with a wide range of biological activities represented from the species (Li et al., 2018). To broaden the chemical diversity of cytochalasans with interesting activity, three novel cytochalasans derivatives, termed chaetoglobosins B\textsubscript{1}–B\textsubscript{3} (1–3) were isolated from the chemical modification of an extract of C. madrasense 375, and four known metabolite chaetoglobosins (4–7) were also identified. Compounds 1–3 represented the first examples of hydrazine-containing heterocycle fused into the macrocyclic of cytochalasans. The structures of 1–3 were elucidated by means of spectroscopic data, quantum-chemical ECD simulation. In the antiproliferative activity.

Frontiers in Chemistry | www.frontiersin.org 6 April 2021 | Volume 9 | Article 620589

The known cytochalasin alkaloid, chaetoglobosin B (4), chaetoglobosin D (5), chaetoglobosin E (6), and cytoglobosin A (7) were identified by comparing their 1D NMR and ESI-MS data with those in the scientific literature. To make sure that 3 is not a scalemic or racemic mixture, an HPLC analysis was carried out on a Agilent 1200 (Agilent Technologies, USA) system with a chiral column Daicel Chiralcel OD-H column (Supplementary Figure 38). The result indicated that 3 is a monomeric compound.
assay, compound 6 displayed potent inhibition activity against four human cancer cell lines (A549, SW620, MDA-MB-231, and HCC827), as well as two drug-resistant (gefitinib, osimertinib) HCC827 cell lines; it is the first time to evaluate the drug-resistant activity of cytochalasans. However, the inhibition activity of new compounds 1–3 on three cancer cell lines (SW620, MDA-MB-231, and HCC827) was weaker than unreacted chaetoglobosin B (4). Only compound 1 exhibited selected antiproliferative
activity on non-small-cell lung carcinoma A549 cells. The results indicated the active sites of 1–3 maybe at C-19–C-23 which were blocked by hydrazine-containing heterocycle. Thus, chemical modification of extract of Chaetomium madrasense provides useful insights that natural products could be an alternative source to generate biological molecules with a novel structure for drug screening through chemical diversification.

DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

AUTHOR CONTRIBUTIONS

QG and LC conceived ideas, designed experiments, and wrote the original draft. QG, ZY, and JZ performed the experiments. JC contributed to cytotoxicity testing. YR and BY contributed to the chemical diversification and plausible synthesis pathway. WY, GD, and WZ analyzed the data and critically reviewed the manuscript. XW and GD provided the fungal material. All authors listed have approved the work for publication.

FUNDING

This work was supported by the Key Scientific Research Projects of Colleges and Universities in Henan Province (20B3500004), Tackling-plan Project of Henan Department of Science and Technology (212102310325 and 212102310243), and the special fund project of Zhengzhou basic and applied basic research (ZZSZX202003).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fchem.2021.620589/full#supplementary-material

REFERENCES

Bradhshaw, J., Butina, D., Dunn, A. J., Green, R. H., Hajek, M., Jones, M. M., et al. (2001). A rapid and facile method for the dereplication of purified natural products. J. Nat. Prod. 64, 1541–1544. doi: 10.1021/np010284g

Chen, J. H., Wang, W. F., Wang, H. Y., Liu, X., and Guo, X. (2014). Combination treatment of ligustrazine piperazine derivate DL114 and adriamycin inhibits progression of resistant breast cancer through inhibition of the EGFR/PI3K/Akt survival pathway and induction of apoptosis. Drug. Discov. Ther. 8, 33–41. doi: 10.5582/ddt.8.33

Chen, L., Qin, J. C., Zhang, Y. G., and Ding, G. (2020). Diagnostically analyzing 1H NMR spectra of sub-types in chaetoglobosins for dereplication. RSC. Adv. 10, 1946–1955. doi: 10.1039/C9RA10434H

Cui, C. M., Li, X. M., Li, C. S., Proksch, P., and Wang, B. G. (2010). Cytoglobinins A-G, cytochalasans from a marine-derived endophytic fungus, Chalotomium globosum QEN-14. J. Nat. Prod. 73, 729–733. doi: 10.1021/np900569r

Feher, M., and Schmidt, J. M. (2003). Property distributions: differences between drugs, natural products, and molecules from combinatorial chemistry. J. Chem. Inf. Comp. Sci. 34, 218–227. doi: 10.1021/ci0200467

Gao, W., He, Y., Li, F., Chai, C., Zhang, J., and Guo, J. (2019). Anti-bacterial activity against drug-resistant microbial pathogens of cytochalasan alkaldoids from the arthropod-associated fungus Chaetomium globosum TW1-1. Bioorg. Chem. 83, 98–104. doi: 10.1016/j.bioorg.2018.10.020

Garcia, P., Salazar, M. O., Ramallo, I. A., and Furlan, R. L. E. (2016). A new fluorinated tyrosinase inhibitor from a chemically engineered essential oil. ACS. Comb. Sci. 18, 283–286. doi: 10.1021/acscombsci.6b00004

Guo, Q. F., Yin, Z. H., Zhang, J. J., Kang, W. Y., Wang, X. W., G., et al. (2019). Chaetomadrasins A and B, two new cytotoxic cytochalasans from desert soil-derived fungus Chaetomium madrasense 375. Molecules. 24, 3240. doi: 10.3390/molecules24183240

Kikuchi, H., Sakurai, K., and Oshima, Y. (2014). Development of diversity-enhanced extracts of Cencuma zedoaria and their new sesquiterpene-like compounds. Org. Lett. 16, 1916–1919. doi: 10.1021/ol5004324

Li, H., Liao, Z. B., Tang, D., Han, W. B., Zhang, Q., and Gao, J. M. (2018). Polyketides from two Chaetomium species and their biological functions. J. Antibiot. 71, 677–681. doi: 10.1038/s41429-018-0047-x

Lopez, S. N., Ramallo, I. A., Sierra, M. G., Zacchino, S. A., and Furlan, R. L. E. (2007). Chemically engineered extracts as an alternative source of bioactive natural product-like compounds. Proc. Natl. Acad. Sci. U.S.A. 104, 441–444. doi: 10.1073/pnas.0608438104

Mendez, L., Salazar, M. O., Ramallo, I. A., and Furlan, R. L. E. (2011). Brominated extracts as source of bioactive compounds. ACS. Com. Sci. 13, 200–204. doi: 10.1021/acs.jnatprod.5b01055

Newman, D. J., and Cragg, G. M. (2016). Natural products as sources of new drugs from 1981 to 2014. J. Nat. Prod. 79, 629–661. doi: 10.1021/acs.jnatprod.5b01055

TABLE 3 | Cytotoxicity of compounds 1–7 (IC50 µM).

| Compounds | A549 | HCC827 | SW620 | MDA-MB-231 |
|-----------|------|--------|-------|-------------|
| 1         | 11.0 | >20    | >20   | >20         |
| 2         | >20  | >20    | >20   | >20         |
| 3         | >20  | >20    | >20   | >20         |
| 4         | >20  | 11.6   | 8.7   | 11.4        |
| 5         | 6.9  | 6.9    | 7.7   | 10.6        |
| 6         | 2.0  | 1.7    | 2.9   | 9.9         |
| 7         | >20  | >20    | 13.9  | >20         |
| cis-platin | 6.4  | 4.5    | 4.2   | 47.7 |

aUsed as a positive control.

TABLE 4 | Cytotoxicity of compound 6 against two drug-resistant HCC827 cells (Gefitinib-resistant, Osimertinib-resistant) (IC50 µM).

| Compounds | HCC827 (Gefitinib-resistant strain) | HCC827 (Osimertinib-resistant strain) |
|-----------|------------------------------------|--------------------------------------|
| 6         | 5.1                                | 2.8                                  |
| Gefitinib  | 65.1                               | _b                                  |
| Osimertinib| 11.9                               | 11.9                                 |

aUsed as positive controls. bNot tested.
Guo et al. Cytochalasans From Chaetomium Madrasense

Ramallo, I. A., Sierra, M. G., and Furlan, R. L. E. (2012). Discovery of beta-glucosidase inhibitors from a chemically engineered extract prepared through ethanolysis. J. Med. Chem. 8, 112–117. doi: 10.2174/157340612799278559

Salazar, M. O., Micheloni, O., Escalante, A. M., and Furlan, R. L. E. (2011). Discovery of a beta-glucosidase inhibitor from a chemically engineered extract prepared through sulfonylation. Mol. Divers. 15, 713–719. doi: 10.1007/s11030-010-9301-2

Scherlach, K., Boettger, D., Remme, N., and Hertweck, C. (2010). The chemistry and biology of cytochalasans. Nat. Prod. Rep. 27, 869–886. doi: 10.1039/b903913a

Sekita, S., Yoshihira, K., and Natori, S. (1982). Chaetoglobosins, cytotoxic 10-(indol-3-yl)-[13] cytochalasans from Chaetomium spp. II. Structures of Chaetoglobosins A, B, and D. Chem. Pharm. Bull. 30, 1618–1628. doi: 10.1248/cpb.30.1618

Sekita, S., Yoshihira, K., and Natori, S. (1983). Chaetoglobosins, cytotoxic 10-(indol-3-yl)-[13] cytochalasans from Chaetomium spp. IV. Carbon-13 nuclear magnetic resonance spectra and their application to a biosynthetic study. Chem. Pharm. Bull. 31, 490-498. doi: 10.1248/cpb.31.490

Sekita, S., Yoshihira, K., Natori, S., and Kuwano, H. (1976). Structures of chaetoglobosins C, D, E, and F, cytotoxic indol-3-yl-[13] cytochalasans from Chaetomium globosum. Tetrahedron. Lett. 17, 1351–1354. doi: 10.1016/S0040-4039(00)78062-2

Wolffender, J. L., and Queiroz, E. F. (2012). Chemical diversity of natural resources and the bioactivity of their constituents. CHIMIA. 66, 324–329. doi: 10.2533/chimia.2012.324

Wu, T., Jiang, C., Wang, L., Morris-Natschke, S. L., Miao, H., Gu, L., et al. (2015). 3,5-Diarylpyrazole derivatives obtained by ammonolysis of the total flavonoids from Chrysanthemum indicum extract show potential for the treatment of Alzheimer’s disease. J. Nat. Prod. 78, 1593–1599. doi: 10.1021/acs.jnatprod.5b00156

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Guo, Chen, Ren, Yin, Zhang, Yang, Wang, Yin, Zhang, Ding and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.